Teva Pharmaceuticals

I’m delighted to welcome Evan Lippman as our new Executive Vice President of Business Development. As we accelerate Teva’s #PivottoGrowth strategy, focused business development efforts play a key role in expanding the innovation of our promising pipeline and fostering key partnerships. Evan is a highly accomplished executive with a wealth of experience in corporate finance, business development and operational leadership across both large pharmaceutical companies and emerging biotechnology firms. I am confident that his expertise and leadership will be invaluable to accelerate Teva's momentum bringing innovative therapies and impactful medicines to patients worldwide through strategic partnerships and collaborations across the academic, healthcare and technology sectors. Welcome aboard, Evan!  #TevaPharm #PivotToGrowth #WeAreAllInForBetterHealth

Our senior leadership team met in Athens last week to kick off the #PivotToGrowth acceleration after eight consecutive quarters of growth.   What made this gathering of 100+ global leaders truly special? Above all, it was witnessing the shared drive for excellence and the power of collaboration across geographies and functions. The energy in the Summit was palpable - dynamic discussions, shared expertise, and a collective commitment to operational excellence.   As we break through barriers and step into the next phase of our strategy, we're poised to move forward with momentum, operating across the full spectrum of innovation to deliver better health worldwide.   #Tevapharm #Leadership #Strategy #Acceleration

Just got back from our Teva Pharmaceuticals Senior Leadership Summit in Greece, where over 100 incredible leaders from around the world came together to kick off our next phase of growth. Together we analysed our progress to date and how over the past two years, we’ve delivered eight consecutive quarters of growth. Now, we’re entering the next phase - Acceleration. The discussions were dynamic, focused, and clear: we have momentum, and we have the strategy. Our ability to execute across our full spectrum of innovation with operational excellence will define our continued success. I feel energized by the passion, expertise, and commitment of our leadership teams. Together, we are shaping a stronger Teva - one that will continue making a real impact on patients and healthcare systems worldwide. #TevaPharm #PivotToGrowth #Acceleration #Leadership

Join us in celebrating Jamie Zona, Senior Manager, Commercial Training, and Beth Rody, VP, Global Clinical Operations – Generics, who have been recognized as this year’s Healthcare Businesswomen’s Association (HBA) Rising Star and Luminary! 🌟 Jamie and Elizabeth exemplify outstanding leadership, mentorship and dedication, driving meaningful progress within Teva and the healthcare industry. Their achievements have inspired those around them, reinforcing the power of strong leadership. For more than a decade, Teva has proudly partnered with the Healthcare Businesswomen’s Association, championing their mission to empower and elevate women in healthcare. We celebrate the incredible contributions of leaders who push boundaries, innovate and shape our industry. Learn more about our Rising Star and Luminary and how the HBA has influenced their careers: https://bit.ly/43E5rfH  #HBAImpact #TevaUSA #WomenatTeva #RisingStar #Luminary 

Try to say it out loud - pharmacokinetics, pharmacokinetics, pharmacokinetics. Did you manage to repeat it 3 times in a row? 😅 We asked our R&D team to share the words they use most in their daily clinical work. Let’s just say – we expected some jargon, but wow, they really delivered! What’s the word you catch yourself saying on repeat at work? Drop them below 👇 Dana-Rae Peleg Chen, Michal Mossberg, Dr. Vicky Goler Baron, Yonni Shem-Tov, Avia Merenlender-Wagner, Ianai Fishbein PhD, Inbal Ben-Eliezer. #TevaCareers #LifeAtTeva #Tevapharm

Sure, anime art is cool, but AI-powered clinical development? 𝑇ℎ𝑎𝑡'𝑠 where things get truly life changing. 💚 Discover how Teva is using AI to make a real, tangible difference for patients: https://lnkd.in/dCcwxq2q #AIinClinicalTrials #Tevapharm #SpectrumOfInnovation #Anime #TevaCareers

Bipolar Disorder I (BP-I) is a manic-depressive condition that can greatly impact quality of life. Approximately 3.4 million adults in the U.S. will experience BP-I in their lifetime. Despite its prevalence, difficulties in diagnosis coupled with longstanding stigma and misconceptions around mental health have become barriers that prevent patients from getting the care they need. Whether it's for those living with BP-I or other mental health conditions, understanding the patient perspective, and what types of treatment options work best for their daily routine, is what steers our research and innovative medicines pipeline. Supporting patients also requires working with advocacy and public sector partners to champion programs that will help reduce stigma and facilitate conversations on how to manage these conditions. This #WorldBipolarDay, as we embrace those who are #Bipolarstrong, we encourage everyone to think about what they can do to be a part of the solution in combatting stigma in their communities: https://ow.ly/yE9m50VpZXE

Multiple system atrophy (MSA) is a relentless degenerative disease – a profound understatement to describe its devastating impact. Within five years of diagnosis, it’s expected that over half of those with MSA will be wheelchair-bound, and life expectancy is about 6-10 years. It’s #MSAAwarenessMonth, a crucial opportunity to spotlight this rare disease. MSA systematically destroys the brain’s ability to regulate movement, balance, and essential autonomic functions (like blood pressure control and bladder regulation). Often misdiagnosed as Parkinson’s disease, MSA is far less common and doesn’t respond well to existing therapies. While the exact cause is unknown, a critical aspect of MSA lies in the brain, where a protein known as alpha-synuclein misfolds and aggregates. When these protein chains clump together, they become toxic and contribute to cellular degradation, creating holes in brain cells. At Teva, we’re committed to tackling the world’s toughest health challenges. Within our pipeline, we’re exploring the potential of a small molecule to bind these alpha-synuclein proteins in the brain, potentially preventing aggregation. While much work remains, I have unwavering faith in the innovation and potential of our R&D team. We are steadfast in our mission to unlock what’s next in science and to support patients worldwide. Where we can all start today is to commit to educating ourselves about MSA, its impact, and understand the unique patient perspective and unmet need in this space. Read more here: https://lnkd.in/ekXwNVDa #TogetherWeCanHelpPatients #TevaPharm #TevaRnDThePlaceToBe #MultipleSystemAtrophy #Raredisease

For over 120 years, Teva has been a different kind of pharmaceutical company – one that operates across the full spectrum of innovation to continuously better health worldwide. Our legacy is built on being stronger, bolder and simpler in the way we operate and relentless in our growth. We are constantly looking ahead to understand what's next in science, for patients, people, and society. Because when it comes to health, good is not enough for us. Moving forward together with science that treats, inspired by the people we serve. We are all in for better health. #Tevapharm #WeAreAllInForBetterHealth #PivottoGrowth

"Our 'Step-Up Innovation' program gives every employee the opportunity to present their innovative ideas to simplify processes or accelerate studies," shares Navdeep Boparai, Head of Global Statistics, Data Science and Medical Writing at Teva. "Our entrepreneurial culture thrives on fresh thinking – encouraging employees to grow and make their mark", she adds. Watch the video to discover Navdeep's favorite part of working at Teva R&D. 👇 What's her advice for young professionals in the field? Click here to find out >> https://ow.ly/p44950Vo1ac #TevaPharm #TevaCareers #LifeatTeva